Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms
暂无分享,去创建一个
A. Gjedde | P. Cumming | P Cumming | A Gjedde
[1] A. Gjedde,et al. Effect of catechol‐O‐methyltransferase inhibition on brain uptake of [18F]fluorodopa: Implications for compartmental modelling and clinical usefulness , 1998, Synapse.
[2] A. Gjedde,et al. [3H]DOPA Formed from [3H]Tyrosine in Living Rat Brain Is Not Committed to Dopamine Synthesis , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] J. Steinbach,et al. CHAPTER 43 – HPLC Analysis of the Metabolism of 6-[18F]Fluoro-L-DOPA in the Brain of Neonatal Pigs , 1998 .
[4] Albert Gjedde,et al. The kinetic behaviour of [3H]DOPA in living rat brain investigated by compartmental modelling of static autoradiograms , 1997, Journal of Neuroscience Methods.
[5] A. Gjedde,et al. In Vivo Regulation of DOPA Decarboxylase by Dopamine Receptors in Rat Brain , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] A. Gjedde,et al. On the accuracy of an [18F]FDOPA compartmental model: evidence for vesicular storage of [18F]fluorodopamine in vivo , 1997, Journal of Neuroscience Methods.
[7] K. Meguro,et al. Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: A double-tracer PET study , 1997, Neurology.
[8] M E Phelps,et al. Biological imaging and the molecular basis of dopaminergic diseases. , 1997, Biochemical pharmacology.
[9] D. Brooks,et al. Dopaminergic function in patients with posttraumatic parkinsonism: An 18F-dopa PET study , 1997, Neurology.
[10] Björn Gustavii,et al. Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.
[11] V. Oikonen,et al. [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[12] S J Kish,et al. [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease , 1997, Neurology.
[13] J E Holden,et al. Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: implications for PET dopamine studies. , 1997, Life sciences.
[14] S. Shelton,et al. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoroDOPA. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] B. Snow,et al. Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication , 1997, Neurology.
[16] Bengt Långström,et al. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease , 1997, Annals of neurology.
[17] J. Wu,et al. Increased dopamine activity associated with stuttering , 1997, Neuroreport.
[18] D J Burn,et al. Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study , 1997, Annals of neurology.
[19] K Wienhard,et al. Functional effects of striatal dysfunction in Parkinson disease. , 1997, Archives of neurology.
[20] T. Taniwaki,et al. Positron emission tomography (PET) in Machado-Joseph disease , 1997, Journal of the Neurological Sciences.
[21] Paul Cumming,et al. The effect of unilateral neurotoxic lesions to serotonin fibres in the medial forebrain bundle on the metabolism of [3H]DOPA in the telencephalon of the living rat , 1997, Brain Research.
[22] B. Långström,et al. L‐DOPA modulates striatal dopaminergic function in vivo: Evidence from PET investigations in nonhuman primates , 1997, Synapse.
[23] D J Brooks,et al. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. , 1996, Brain : a journal of neurology.
[24] Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography , 1996, Journal of the Neurological Sciences.
[25] A. Kishore,et al. Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family , 1996, Neurology.
[26] Masayuki Sasaki,et al. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study , 1996, Journal of the Neurological Sciences.
[27] T. Ishikawa,et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] A. Duchemin,et al. Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. , 1996, European journal of pharmacology.
[29] S. Cherry,et al. Longitudinal Behavioral and 6-[18F]Fluoro-l-DOPA-PET Assessment in MPTP-Hemiparkinsonian Monkeys , 1996, Experimental Neurology.
[30] T. Ishikawa,et al. Fluorodopa Positron Emission Tomography with an Inhibitor of Catechol-O-Methyltransferase: Effect of the Plasma 3-O-Methyldopa Fraction on Data Analysis , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] Y. Itoyama,et al. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration , 1996, Journal of the Neurological Sciences.
[32] J. Brandt,et al. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging , 1996, Neurology.
[33] Adriaan A. Lammertsma,et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease , 1996, Journal of Neuroscience Methods.
[34] J S Fowler,et al. PET evaluation of the dopamine system of the human brain. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] B. Siesjö,et al. Characteristics of postischemic seizures in hyperglycemic rats , 1996, Journal of the Neurological Sciences.
[36] S. Cherry,et al. Radiofluorinated L-m-Tyrosines: New In-Vivo Probes for Central Dopamine Biochemistry , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] R. Surtees,et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. , 1996, Human molecular genetics.
[38] M. Ernst,et al. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. , 1996, The New England journal of medicine.
[39] A. Levey,et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users , 1996, Nature Medicine.
[40] Alan C. Evans,et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[41] D J Brooks,et al. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.
[42] C. Nahmias,et al. Modeling of fluorine-18-6-fluoro-L-Dopa in humans. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[43] C. Patlak,et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] T. Ishikawa,et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] M E Phelps,et al. 6‐[18F]fluoro‐L‐DOPA‐PETstudies show partial reversibility of long‐term effects of chronic amphetamine in monkeys , 1996, Synapse.
[47] P. McGuffin,et al. Amphetamine and vigabatrin down regulate aromatic L-amino acid decarboxylase mRNA levels. , 1996, Brain research. Molecular brain research.
[48] J. Missimer,et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. , 1995, Archives of neurology.
[49] D J Brooks,et al. Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[50] J. Hietala,et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.
[51] A. Gjedde,et al. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. , 1995, Biochemical pharmacology.
[52] A. Gjedde,et al. Regulation of DOPA Decarboxylase Activity in Brain of Living Rat , 1995, Journal of neurochemistry.
[53] F. Vingerhoets,et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease , 1995, Annals of neurology.
[54] J. Haycock,et al. Striatal 3,4‐dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies? , 1995, Annals of neurology.
[55] Alan C. Evans,et al. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] C. Nahmias,et al. A probe for intracerebral aromatic amino‐acid decarboxylase activity: Distribution and kinetics of [18F]6‐fluoro‐L‐m‐tyrosine in the human brain , 1995, Movement disorders : official journal of the Movement Disorder Society.
[57] C. Marsden,et al. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy , 1995, Annals of neurology.
[58] D J Brooks,et al. L‐Dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles , 1995, Movement disorders : official journal of the Movement Disorder Society.
[59] B. Pate,et al. Routes of administration and effect of carbidopa pretreatment on 6-[18F]fluoro-L-dopa/PET scans in non-human primates. , 1995, Life Science.
[60] Z. Rossetti,et al. Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity. , 1995, European journal of pharmacology.
[61] Alan C. Evans,et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[62] A. Gjedde,et al. A Kinetic Analysis of 6‐[18F]Fluoro‐l‐Dihydroxyphenylalanine Metabolism in the Rat , 1994, Journal of neurochemistry.
[63] M Schulzer,et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.
[64] M Schulzer,et al. Age‐dependent decline of nigrostriatal dopaminergic function: A positron emission tomographic study of grandparents and their grandchildren , 1994, Annals of neurology.
[65] C. Nahmias,et al. The Distribution and Kinetics of [18F]6-Fluoro-3-O-Methyl-l-Dopa in the Human Brain , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[66] G. Sawle,et al. The effect of entacapone (OR‐611) on brain [18F]‐6‐L‐fluorodopa metabolism , 1994, Neurology.
[67] A. Gjedde,et al. Brain uptake of α‐[14C]methyl‐para‐tyrosine in the rat , 1994 .
[68] V. Dhawan,et al. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[69] J. Langston,et al. Parkinsonism caused by petroleum waste ingestion , 1994, Neurology.
[70] A. Luxen,et al. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa. , 1994, European journal of pharmacology.
[71] J. Nutt,et al. Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients , 1994, Neurology.
[72] J. Holden,et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[73] Hirohide Takahashi,et al. Positron emission tomographic studies of dopa‐responsive dystonia and early‐onset idiopathic parkinsonism , 1993, Annals of neurology.
[74] G. Chiro,et al. 6-[18F]Fluoro-l-dihydroxyphenylalanine metabolism and positron emission tomography aftercatechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys , 1993, Brain Research.
[75] B. Snow,et al. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning , 1993, The Lancet.
[76] Alan C. Evans,et al. Striatal L‐DOPA Decarboxylase Activity in Parkinson's Disease In Vivo: Implications for the Regulation of Dopamine Synthesis , 1993, Journal of neurochemistry.
[77] B. Pate,et al. The transport of L‐6‐fluorodopa and its metabolites from blood to cerebrospinal fluid and brain , 1993, Annals of neurology.
[78] D B Calne,et al. Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.
[79] C. Patlak,et al. Striatal 18F-DOPA Uptake: Absence of an Aging Effect , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[80] H. Kimura,et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.
[81] A. Boulton,et al. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. , 1993, European journal of pharmacology.
[82] A. Gjedde,et al. Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[83] J. Hubble,et al. Aromatic L‐Amino Acid Decarboxylase Activity of Mouse Striatum Is Modulated via Dopamine Receptors , 1993, Journal of neurochemistry.
[84] Alan C. Evans,et al. Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to Normal Subjects , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[85] A. Gjedde,et al. 6-[18F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[86] B. Snow,et al. PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report. , 1993, Advances in neurology.
[87] D. Calne,et al. Clinical heterogeneity of dopa-responsive dystonia: PET observations. , 1993, Advances in neurology.
[88] Alan C. Evans,et al. Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa , 1993, Movement disorders : official journal of the Movement Disorder Society.
[89] S. Shelton,et al. Visualization of dopamine nerve terminals by positron tomography using [18 F]fluoro-β-fluomethylene-m-tyrosine , 1992, Brain Research.
[90] Scott T. Grafton,et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.
[91] H. Fibiger,et al. Formation and Clearance of Interstitial Metabolites of Dopamine and Serotonin in the Rat Striatum: An In Vivo Microdialysis Study , 1992, Journal of neurochemistry.
[92] J. Marshall,et al. Elevated NMDA receptors in parkinsonian striatum. , 1992, Neuroreport.
[93] B. Snow,et al. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido‐ponto‐nigral degeneration , 1992, Annals of neurology.
[94] J. Holden,et al. Plasma L-[18F]6-Fluorodopa Input Function: A Simplified Method , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[95] B Horwitz,et al. Age-related differences in volumes of subcortical nuclei, brain matter, and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. , 1992, Archives of neurology.
[96] J C Mazziotta,et al. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[97] J. Palacios,et al. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: A quantitative autoradiographic study using [3H]mazindol , 1992, Neuroscience.
[98] Alan C. Evans,et al. 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain , 1992, Annals of neurology.
[99] Yasuyoshi Watanabe,et al. Assessment of dopamine and its metabolites in the intracellular and extracellular compartments of the rat striatum after peripheral administration ofl-[11C]DOPA , 1992, Brain Research.
[100] S. Kish,et al. Aging Produces a Specific Pattern of Striatal Dopamine Loss: Implications for the Etiology of Idiopathic Parkinson's Disease , 1992, Journal of neurochemistry.
[101] Richard S. J. Frackowiak,et al. Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6‐L‐fluorodopa studies in two patients with putaminal implants , 1992, Annals of neurology.
[102] A. Boulton,et al. Regulation of Aromatic l‐Amino Acid Decarboxylase by Dopamine Receptors in the Rat Brain , 1992, Journal of neurochemistry.
[103] B. Långström,et al. Cerebral uptake and utilization of therapeutic [β‐11C]‐L‐DOPA in Parkinson's disease measured by positron emission tomography. Relations to motor response , 1992, Acta neurologica Scandinavica.
[104] J. Rinne,et al. [18F]‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462) , 1992, Neurology.
[105] J. Roth,et al. Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. , 1992, Reviews of physiology, biochemistry and pharmacology.
[106] M E Phelps,et al. L-6-[18F]Fluoro-DOPA Metabolism in Monkeys and Humans: Biochemical Parameters for the Formulation of Tracer Kinetic Models with Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[107] Scott T. Grafton,et al. Kinetics and Modeling of l-6-[18F]Fluoro-DOPA in Human Positron Emission Tomographic Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[108] T. Aigner,et al. Distribution and Kinetics of 3-O-Methyl-6-[18F]fluoro-L-DOPA in the Rhesus Monkey Brain , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[109] V. Ibáñez,et al. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: A positron emission tomographic study , 1991, Annals of neurology.
[110] B. Långström,et al. Low brain uptake of L‐[11C]5‐hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers , 1991, Acta psychiatrica Scandinavica.
[111] B. Pate,et al. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[112] Alan C. Evans,et al. Dopa decarboxylase activity of the living human brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[113] J. Hoffman,et al. 6-[18F]Fluoro-l-DOPA metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography , 1991, Brain Research.
[114] W. Martin,et al. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[115] Richard S. J. Frackowiak,et al. Striatal function in normal aging: Implications for Parkinson's disease , 1990, Annals of neurology.
[116] J C Mazziotta,et al. 6‐[18F]Fluoro‐L‐DOPA probes dopamine turnover rates in central dopaminergic structures , 1990, Journal of neuroscience research.
[117] C D Marsden,et al. Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.
[118] C D Marsden,et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. , 1990, Brain : a journal of neurology.
[119] A. Gjedde,et al. Blood—Brain Transfer and Metabolism of 6-[18F]Fluoro-L-DOPA in Rat , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[120] A. Eisen,et al. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. , 1990, Archives of neurology.
[121] W. Martin,et al. Positron emission tomography in Shy‐Drager syndrome , 1990, Annals of neurology.
[122] A. Luxen,et al. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats. , 1990, Biochemical pharmacology.
[123] D. Riemann,et al. The effects of total sleep deprivation and subsequent treatment with clomipramine on depressive symptoms and sleep electroencephalography in patients with a major depressive disorder * , 1990, Acta psychiatrica Scandinavica.
[124] G. Antoni,et al. Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography , 1990, Acta neurologica Scandinavica.
[125] A. Luxen,et al. The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans. , 1990, Life sciences.
[126] Y. Agid,et al. Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.
[127] C. Patlak,et al. Nigrostriatal function in humans studied with positron emission tomography , 1989, Annals of neurology.
[128] Scott T. Grafton,et al. 4‐[18F]Fluoro‐L‐m‐Tyrosine: An L‐3,4‐Dihydroxyphenylalanine Analog for Probing Presynaptic Dopaminergic Function with Positron Emission Tomography , 1989, Journal of neurochemistry.
[129] P. Männistö,et al. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. , 1989, Journal of medicinal chemistry.
[130] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[131] C. Nahmias,et al. Metabolites of 6-[18F]fluoro-L-dopa in human blood. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[132] J. Mukherjee,et al. Radiobrominated m-tyrosine analog as potential CNS L-dopa pet tracer. , 1988, Biochemical and biophysical research communications.
[133] M. Häusser,et al. Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. , 1988, Biochemical pharmacology.
[134] A. Gjedde. Exchange diffusion of large neutral amino acids between blood and brain , 1988 .
[135] P. Cumming,et al. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. , 1987, Biochemical Pharmacology.
[136] C Nahmias,et al. Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.
[137] D. Goldstein,et al. Neuronal source of plasma dihydroxyphenylalanine. , 1987, The Journal of clinical endocrinology and metabolism.
[138] L. Dyck. Effect of monofluoromethyldopa (MFMD) on trace amine levels. , 1987, Life sciences.
[139] E. Mcgeer,et al. The Metabolism of [18F]6‐Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Hooded Rat , 1987, Journal of neurochemistry.
[140] P. Cumming,et al. Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. , 1986, Life sciences.
[141] Richard S. J. Frackowiak,et al. Inhibition of L‐{18F}fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography , 1986, Annals of neurology.
[142] T Jones,et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[143] B. Westerink,et al. Effect of Various Centrally Acting Drugs on the Efflux of Dopamine Metabolites from the Rat Brain , 1986, Journal of neurochemistry.
[144] P. J. Lewis,et al. Inhibition of Monoamine Oxidase Selectively in Brain Monoamine Nerves Using the Bioprecursor (E‐β‐Fluoromethylene‐m‐Tyrosine (MDL 72394), a Substrate for Aromatic L‐Amino Acid Decarboxylase , 1985, Journal of neurochemistry.
[145] C. Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[146] S. Parvez,et al. Simple purification of aromatic L-amino acid decarboxylase from human pheochromocytoma using high-performance liquid chromatography. , 1985, Analytical biochemistry.
[147] L. Potter,et al. A pre-positron emission tomography study of l-3,4-dihydroxy-[3H]phenylalanine distribution in the rat , 1985, Neuroscience Letters.
[148] R. Micetich,et al. Brain levels of 5-hydroxytryptamine, tryptamine and 2-phenylethylamine in the rat after administration of N-cyanoethyltranylcypromine , 1984, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[149] C. Nahmias,et al. Central Dopaminergic Pathways in Hemiparkinsonism Examined by Positron Emission Tomography , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[150] M. Horne,et al. The cerebral metabolism of L-dihydroxyphenylalanine. An autoradiographic and biochemical study. , 1984, Pharmacology.
[151] C. Nahmias,et al. Striatal dopamine metabolism in living monkeys examined by positron emission tomography , 1983, Brain Research.
[152] C. Nahmias,et al. Dopamine visualized in the basal ganglia of living man , 1983, Nature.
[153] C S Patlak,et al. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[154] Albert Gjedde,et al. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examination , 1982, Brain Research Reviews.
[155] R. Wurtman,et al. Aromatic L‐amino acid decarboxylase in rat corpus striatum , 1981, Neurology.
[156] Albert Gjedde,et al. High‐ and Low‐Affinity Transport of D‐Glucose from Blood to Brain , 1981, Journal of neurochemistry.
[157] M. Tanaka,et al. Autoradiographic studies on distribution of L-3,4-dihydroxyphenylalanine (L-DOPA)-14C and L-5-hydroxytryptophan (L-5-HTP)-14C in the cat brain. , 1980, Japanese journal of pharmacology.
[158] E. Hoffman,et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.
[159] J. Korf,et al. TURNOVER OF FREE AND CONJUGATED (SULPHONYLOXY) DIHYDROXYPHENYLACETIC ACID AND HOMOVANILLIC ACID IN RAT STRIATUM , 1979, Journal of neurochemistry.
[160] S. Bouchard,et al. Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat. , 1979, Canadian journal of biochemistry.
[161] A. Alavi,et al. The [18F]Fluorodeoxyglucose Method for the Measurement of Local Cerebral Glucose Utilization in Mane , 1979, Circulation research.
[162] W. Vaalburg,et al. Rapid decar☐ylation of carbon-11 labelleddl-dopa in the brain: A potential approach for external detection of nervous structures , 1978, Brain Research.
[163] P. Davies,et al. REGIONAL DISTRIBUTION OF ENZYMES ASSOCIATED WITH NEUROTRANSMISSION BY MONOAMINES, ACETYLCHOLINE AND GABA IN THE HUMAN BRAIN , 1978, Journal of neurochemistry.
[164] M. Reivich,et al. THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.
[165] S. Fahn,et al. 3-O-methyl metabolites of catecholamines: automated fluorometric assay and their plasma levels in patients receiving levodopa and carbidopa. , 1974, Biochemical medicine.
[166] S. Udenfriend,et al. Changes in tyrosine hydroxylase and dopa decarboxylase induced by pharmacological agents. , 1972, Pharmacological reviews.
[167] O. Hornykiewicz,et al. Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions , 1970, Science.
[168] S. Udenfriend,et al. Preparation and properties of a homogeneous aromatic L-amino acid decarboxylase from hog kidney. , 1970, Archives of biochemistry and biophysics.
[169] L. Iversen,et al. REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN–II , 1966, Journal of neurochemistry.
[170] L. Iversen,et al. REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐I , 1966, Journal of neurochemistry.